Last update 27 Mar 2025

NB004 (Ningbo Xinwan)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GDC-0570, NB 004, NB-004
+ [1]
Target
PIM
Action
inhibitors
Mechanism
PIM family inhibitors
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid NeoplasmLocally Advanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Ningbo Taikang Pharmaceutical Technology Co. Ltd.
Active Organization
Ningbo Xinwan Pharmaceutical Technology Co., Ltd.Ningbo Taikang Pharmaceutical Technology Co. Ltd.The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with NB004 (Ningbo Xinwan)
NCT05036291
/ RecruitingPhase 1
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered As Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors
100 Clinical Results associated with NB004 (Ningbo Xinwan)
Login to view more data
100 Translational Medicine associated with NB004 (Ningbo Xinwan)
Login to view more data
100 Patents (Medical) associated with NB004 (Ningbo Xinwan)
Login to view more data
100 Deals associated with NB004 (Ningbo Xinwan)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
United States
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
05 Apr 2024
Advanced Malignant Solid NeoplasmPhase 1
China
Ningbo Taikang Pharmaceutical Technology Co. Ltd.
05 Apr 2024
Locally Advanced Malignant Solid NeoplasmPhase 1
United States
Ningbo Xinwan Pharmaceutical Technology Co., Ltd.
01 Oct 2021
Locally Advanced Malignant Solid NeoplasmPhase 1
China
Ningbo Xinwan Pharmaceutical Technology Co., Ltd.
01 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05036291 (NB004, AACR2024)
ManualManual
Phase 1
Solid tumor
18
NB004/NB004+GDC-0570
pbnhcptqlv(izpnjifqcw) = ravamcbnes rlyqtvbsmg (oegkfpmgyl )
Positive
05 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free